Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis

Histochemistry and Cell Biology

Volumn 135, Issue 5, 2011, Pages 427-441

  Baldinger, Anja ^a   Brehm, Bernhard R ^a   Richter, Petra ^a   Bossert, Torsten ^a   Gruen, Katja ^a   Hekmat, Khosro ^a   Kosmehl, Hartwig ^b   Neri, Dario ^c   Figulla, Hans Reiner ^a   Berndt, Alexander ^a   Franz, Marcus ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

^c ETH ZURICH   (Switzerland)

Author keywords

A1 + tenascin C; Aortic valve stenosis; Coronary artery disease; ED A + fibronectin; Extra cellular matrix remodelling; Targeted therapy

Indexed keywords

FIBRONECTIN; IMMUNOGLOBULIN; MESSENGER RNA; TENASCIN;

AGED; AORTA VALVE STENOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOWN REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM; HEART VENTRICLE REMODELING; HEART VENTRICLE SEPTUM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; UPREGULATION;

AGED; AORTIC VALVE STENOSIS; CORONARY ARTERY DISEASE; FEMALE; FIBRONECTINS; GENE EXPRESSION PROFILING; HEART ATRIA; HEART VENTRICLES; HUMANS; MALE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TENASCIN; TISSUE DISTRIBUTION;

EID: 79956224690     PISSN: 09486143     EISSN: 1432119X     Source Type: Journal    
DOI: 10.1007/s00418-011-0809-z     Document Type: Article

References (36)

1. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC (2002) Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 160:2035-2043 (Pubitemid 34663396)
2. Berndt A, Borsi L, Hyckel P, Kosmehl H (2001) Fibrillary code-position of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol 127:286-292
3. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102:4384-4392 (Pubitemid 37494099)
4. Brown RD, Ambler SK, Mitchell MD, Long CS (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45:657-687 Review
5. Cohn NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123:255-278 Review
6. Cohn JN, Ferrari R, Sharpe N (2000) Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569-582 Review
7. Dean RG, Balding LC, Candido R, Burns WC, Cao Z, Twigg SM, Burrell LM (2005) Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 53:1245-1256 (Pubitemid 41331123)
8. Eichhorn ME, Strieth S, Dellian M (2004) Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat 7:125-138 (Pubitemid 38736065)
9. Farhadian F, Contard F, Corbier A, Barrieux A, Rappaport L, Samuel JL (1995) Fibronectin expression during physiological and pathological cardiac growth. J Mol Cell Cardiol 27:981-990 Review
10. Fondard O, Detaint D, Iung B, Choqueux C, Adle-Biassette H, Jarraya M, Hvass U, Couetil JP, Henin D, Michel JB, Vahanian A, Jacob MP (2005) Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26:1333-1341 (Pubitemid 41435466)
11. Franz M, Hansen T, Borsi L, Geier C, Hyckel P, Schleier P, Richter P, Altendorf-Hofmann A, Kosmehl H, Berndt A (2007) A quantitative co-localization analysis of large unspliced tenascin-C(L) and laminin-5/gamma2-chain in basement membranes of oral squamous cell carcinoma by confocal laser scanning microscopy. J Oral Pathol Med 36:6-11 (Pubitemid 44973981)
12. Franz M, Brehm BR, Richter P, Gruen K, Neri D, Kosmehl H, Hekmat K, Renner A, Gummert J, Figulla HR, Berndt A (2010) Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies. J Mol Histol 41:39-50
13. Fujimoto N, Onishi K, Sato A, Terasaki F, Tsukada B, Nozato T, Yamada T, Imanaka-Yoshida K, Yoshida T, Ito M, Hiroe M (2009) Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail 15:898-905
14. Gabler U, Berndt A, Kosmehl H, Mandel U, Zardi L, Müller S, Stelzner A, Katenkamp D (1996) Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants. Heart 75:358-362 (Pubitemid 26155567)
15. Gabrielsen A, Lawler PR, Yongzhong W, Steinbrüchel D, Blagoja D, Paulsson-Berne G, Kastrup J, Hansson GK (2007) Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol 42:870-883 (Pubitemid 46546392)
16. Graham HK, Horn M, Trafford AW (2008) Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol 194:3-21 Review
17. Hall JL, Grindle S, Han X, Fermin D, Park S, Chen Y, Bache RJ, Mariash A, Guan Z, Ormaza S, Thompson J, Graziano J, de Sam Lazaro SE, Pan S, Simari RD, Miller LW (2004) Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol Genomics 17:283-291 (Pubitemid 38924173)
18. Hwang JJ, Allen PD, Tseng GC, Lam CW, Fananapazir L, Dzau VJ, Liew CC (2002) Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 10:31-44 (Pubitemid 135707427)
19. Imanaka-Yoshida K, Hiroe M, Yoshida T (2004) Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 19:517-525 Review
20. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, Conte JV, Tomaselli G, Garcia JG, Hare JM (2005) Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics 21:299-307 (Pubitemid 40903130)
21. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, Suguta M, Yokoyama T, Tada H, Toyama T, Adachi H, Naito S, Oshima S, Nishida T, Kubota S, Takigawa M, Kurabayashi M (2008) Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 10:373-379
22. Mårlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res 14:6515-6524
23. Pedretti M, Soltermann A, Arni S, Weder W, Neri D, Hillinger S (2009) Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 64:28-33
24. Pedretti M, Rancic Z, Soltermann A, Herzog BA, Schliemann C, Lachat M, Neri D, Kaufmann PA (2010) Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis 208:382-389
25. Rybak JN, Trachsel E, Scheuermann J, Neri D (2007) Ligand-based vascular targeting of disease. Chem Med Chem 2:22-40 Review
26. Schliemann C, Neri D (2010) Antibody-based vascular tumor targeting. Recent Results Cancer Res 180:201-216 Review
27. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E (2009) Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 11:R142
28. Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215-262 Review
29. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, Nishioka T, Inada H, Hiroe M, Sakakura T, Yoshida T (2005) Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 167:71-80 (Pubitemid 40884771)
30. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A (2007) Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan. Circ J 71:327-330 (Pubitemid 46409533)
31. Trachsel E, Neri D (2006) Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis. Adv Drug Deliv Rev 58:735-754 Review
32. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405-2413 (Pubitemid 351590471)
33. Weber KT (2004) Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. J Hypertens 22:47-50
34. Wight TN (2008) Arterial remodeling in vascular disease: a key role for hyaluronan and versican. Front Biosci 13:4933-4937 Review
35. Willems IE, Arends JW, Daemen MJ (1996) Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 179:321-325 (Pubitemid 26266413)
36. Yang DC, Ma ST, Tan Y, Chen YH, Li D, Tang B, Chen JS, Su XH, Li G, Zhang X, Yang YJ (2010) Imbalance of matrix metalloproteinases/tissue inhibitor of metalloproteinase-1 and loss of fibronectin expression in patients with congestive heart failure. Cardiology 116:133-141